Japan takes a particularly reactive approach to vaccine adverse events. In 2011 Pfizer's Prevnar and Sanofi's ActHIB vaccines were both suspended following the deaths of four children. This week the spotlight is on GlaxoSmithKline and Merck.
Japanese women can now get medical insurance coverage for breast implants following surgeries due to cancer. A panel from the country's Ministry of Health signed off on the change, Japan Daily Press reports.
After almost two years of discussions and dealmaking, Fujifilm and Dr. Reddy's Laboratories have called off their plot to team up on generics in Japan.
Japan has launched a new public-private partnership, dubbed the Global Health Innovative Technology Fund (GHIT), that brings together several Japanese pharmaceutical companies, nonprofit organizations and academic institutions to find new treatments for AIDS, malaria, tuberculosis, and other diseases that disproportionately affect the world's poor.
Amgen has seemed sorely in need of an Asian expansion strategy as competitors put down eastern roots and seemed to pass it by. But with an agreement this morning with Astellas Pharma to establish a new joint venture in Japan, the world's biggest biotech showed it won't be left behind.
Just a few months after Amgen execs lamented a big Asian gap in their global strategy, the Big Biotech company has joined hands with Astellas to set up a new joint venture in Japan. Amgen is contributing 5 experimental-stage programs to the JV, including their late-stage anti-PCSK9 program for the cholesterol drug AMG-145.
In a sharp reversal of its long neglect of diseases that afflict in the poor in the world's emerging markets, a slate of Japan's top pharma companies have joined a $100 million effort to tackle HIV, malaria, tuberculosis and tropical diseases.
Johnson & Johnson built its R&D rep around blockbuster development deals. Now the pharma giant's drug development arm wants the world to know that there's a comprehensive, global pipeline strategy in play that will deliver more than 10 new product applications over the next 4 years. And new drug development efforts in China and Japan are growing to rival the work it does in the U.S. and Europe.
Tokyo-based Astellas Pharma is rolling out a major R&D restructuring effort, shuttering facilities at its OSI Pharmaceuticals and Perseid Therapeutics subsidiaries and cutting back its work at the Astellas Research Institute of America to focus solely on CNS diseases.
Japan's drugmakers aren't any more immune from generic competition than U.S. pharma companies are. Still the country's second- and third-largest drugmakers are predicting sales growth this year, even as low-cost copies drain away sales of their key products. New drugs are coming in to pick up the slack, the companies said.